Work

2217 IDEC-Y2B8 (90YTTrium ibritumomab tiuxetan) radioimmunotherapy safety results in relapsed or chemotherapy refractory non-Hodgkin's lymphoma patients treated at reduced doses because of pre-existing thrombocytopenia

Year: 1999

Type: article

Source: International Journal of Radiation Oncology*Biology*Physics

DOI: 10.1016/s0360-3016(99)90486-8

Authors: G.A. Wiseman, C.A. White, T.E. Witzig, L.I. Gordon, N. Bartlett, R.L. Levy, J.L. Murray, C. Emmanouilides, S. Spies, C. Zhang, A.J. Grillo-López

Institutions: Northwestern University, Mayo Clinic, The University of Texas MD Anderson Cancer Center, University of California, Los Angeles, Washington University in St. Louis, Ronald Reagan UCLA Medical Center, UCLA Medical Center, Oncology Hematology Care

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2056981410

FWCI:

Cites:

Cited by:

Related to: 10